This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.
Latest papers
Plasma phosphorylated tau181 outperforms [18F] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease.
European journal of neurology · 2024
A Nuclear Magnetic Resonance (NMR)- and Mass Spectrometry (MS)-Based Saturation Kinetics Model of a Bryophyllum pinnatum Decoction as a Treatment for Kidney Stones.
International journal of molecular sciences · 2024
Discordance and Concordance Between Cerebrospinal and [18F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases.
Neurology · 2022
Latest funding
- $956,250
Engineering metabolically stable molecules toward tandem targeting of EGFR, its variant EGFRvIII and DNA for killing stem cells and preventing recurrence in the treatment of glioblastom multiforme (GBM)
CIHR · 2024 · Nominated PI
- $10,855,234
Canadian Consortium of Clinical Trial Training (CANTRAIN) platform: enhancing career preparedness in RCT research targeting different audiences across the continuum
CIHR · 2022 · Co-investigator
- $1,220,175
Exploiting a novel dual-specificity cell cycle inhibitor, KP108 as a therapeutic approach for metastatic breast cancer
CIHR · 2022 · Co-investigator
17 publications.
Plasma phosphorylated tau181 outperforms [18F] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease.
Quispialaya KM, Therriault J, Aliaga A, Tissot C, Servaes S, Rahmouni N, Karikari TK, Benedet AL, Ashton NJ, Macedo AC, Lussier FZ, Stevenson J, Wang YT, Arias JF, Hosseini A, Matsudaira T, Jean-Claude B, Gilfix BM, Zimmer ER, Soucy JP, Pascoal TA, Gauthier S, Zetterberg H, Blennow K, Rosa-Neto P, Alzheimer's Disease Neuroimaging Initiative
A Nuclear Magnetic Resonance (NMR)- and Mass Spectrometry (MS)-Based Saturation Kinetics Model of a Bryophyllum pinnatum Decoction as a Treatment for Kidney Stones.
Chik C, Larroque AL, Zhuang Y, Feinstein S, Smith DL, Andonian S, Ryan AK, Jean-Claude B, Gupta IR
Discordance and Concordance Between Cerebrospinal and [18F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases.
Quispialaya KM, Therriault J, Aliaga A, Zimmermann M, Fernandez-Arias J, Lussier F, Massarweh G, Pascoal T, Soucy JP, Gauthier S, Jean-Claude B, Gilfix B, Vitali P, Rosa-Neto P
Design and Mechanism of Action of a New Prototype of Combi-Molecule "Programed" to Release Bioactive Species at a pH Range Akin to That of the Tumor Microenvironment.
Larroque-Lombard AL, Chatelut E, Delord JP, Imbs DC, Rochaix P, Jean-Claude B, Allal B
Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z, Abdulkarim B, Meehan B, Rak J, Daniel P, Schmitt J, Lauzon N, Eppert K, Duncan HM, Petrecca K, Guiot MC, Jean-Claude B, Sabri S
Temporal Effects of Quercetin on Tight Junction Barrier Properties and Claudin Expression and Localization in MDCK II Cells.
Gamero-Estevez E, Andonian S, Jean-Claude B, Gupta I, Ryan AK
Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities.
Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, Abdulkarim BS
Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
Tian J, Raffa FA, Dai M, Moamer A, Khadang B, Hachim IY, Bakdounes K, Ali S, Jean-Claude B, Lebrun JJ
Examination of VDR/RXR/DRIP205 Interaction, Intranuclear Localization, and DNA Binding in Ras-Transformed Keratinocytes and Its Implication for Designing Optimal Vitamin D Therapy in Cancer.
Jusu S, Presley JF, Williams C, Das SK, Jean-Claude B, Kremer R
Performance of Knowledge-Based Radiation Therapy Planning for the Glioblastoma Disease Site.
Chatterjee A, Serban M, Abdulkarim B, Panet-Raymond V, Souhami L, Shenouda G, Sabri S, Jean-Claude B, Seuntjens J
Engineering metabolically stable molecules toward tandem targeting of EGFR, its variant EGFRvIII and DNA for killing stem cells and preventing recurrence in the treatment of glioblastom multiforme (GBM)
Principal investigators: Jean-Claude, Bertrand J
Keywords: Anti-Cancer Drug Discovery
Canadian Consortium of Clinical Trial Training (CANTRAIN) platform: enhancing career preparedness in RCT research targeting different audiences across the continuum
Principal investigators: Bourbeau, Jean; Anderson, David R; Batist, Gerald; Bell, Emily C; Benoit, Britney L; Collister, David; Dasgupta, Kaberi; Fahim, Christine; Fergusson, Dean A; Filion, Kristian B; Gahagan, Jacqueline C; Goos, Lisa; Khan, Nadia A; King, Malcolm; Li, Linda C; Mitra, Souvik; Morin, Suzanne N; Pilote, Louise; Reiman, Tony; Richer, Lawrence P; Saleh, Ramy R; Sapp, John L; Tomblin Murphy, Gail G; Yeh, Ann E.
Keywords: Clinical Trial Design; Clinical Trial Professional; Clinical Trial Training; Equity, Diversity, And Inclusion Best Practices; Gender-Based Clinical Trial And Analysis; Mentoring Platform; Patient Partner; Professional Education; Research Involving Indigenous People; Training Platform
Exploiting a novel dual-specificity cell cycle inhibitor, KP108 as a therapeutic approach for metastatic breast cancer
Principal investigators: Lebrun, Jean-Jacques
Keywords: Cancer Stem Cell Therapy; Cdk4/6 Inhibitors; Computational Modeling; Drug Development; Dual Targeting Kinase Inhibitors; Metastatic Cancer; Plk1 Inhibitors; Preclinical Models Of Breast Cancer; Structure-Based Drug Discovery And Design; Triple Negative Breast Cancer
Canadian Consortium of Clinical Trial Training (CANTRAIN) platform: enhancing career preparedness in RCT research targeting different audiences across the continuum
Principal investigators: Bourbeau, Jean; Anderson, David R; Batist, Gerald; Bell, Emily C; Benoit, Britney L; Collister, David; Dasgupta, Kaberi; Fahim, Christine; Fergusson, Dean A; Filion, Kristian B; Gahagan, Jacqueline C; Goos, Lisa; Khan, Nadia A; King, Malcolm; Li, Linda C; Mitra, Souvik; Morin, Suzanne N; Pilote, Louise; Reiman, Tony; Richer, Lawrence P; Saleh, Ramy R; Sapp, John L; Tomblin Murphy, Gail G; Yeh, Ann E.
Keywords: Clinical Trial Design; Clinical Trial Professional; Clinical Trial Training; Equity, Diversity, And Inclusion Best Practices; Gender-Based Clinical Trial And Analysis; Mentoring Platform; Patient Partner; Professional Education; Research Involving Indigenous People; Training Platform
From Rational Design To in vivo Evaluation of Dual Covalent Prolyl Oligopeptidase / Fibroblast Activation Protein Inhibitors as Potential Cancer Therapeutics.
Principal investigators: Moitessier, Nicolas R
Keywords: Animal Models; Cancer Therapeutics; Computer-Aided Drug Design; Fibroblast Activation Protein; In Vivo Testing; Medicinal Chemistry; Nmr Spectroscopy; Organic Synthesis; Prolyl Oligopeptidase
Novel unimolecular combination models for selective tumour targeting: A tandem approach to the enhancement of chemoselectivity and abrogation of chemoresistance
Principal investigators: Jean-Claude, Bertrand J
Keywords: Breast; Egf; Egfr; Her1; Her2; Ovarian
Mechanism of action of complex molecules rationally designed to target multiple adverse signaling pathways in tumor cells
Principal investigators: Rao, Suman
Keywords: C-Met; C-Src; Cancer; Combi-Targeting Drugs; Epidermal Growth Factor Receptor; Receptor Tyrosine Kinases; Signal Transduction Pathways
c-Abl-directed molecular re-engineering of chlorambucil to offer new therapeutic options to patients with chronic lymphocytic leukemia (CLL)
Principal investigators: Panasci, Lawrence C
Keywords: Drug Development
CIHR Drug Development Training Program (DDTP)
Principal investigators: Papadopoulos, Vassilios; Bergeron, John J; Damha, Masad J; Hales, Barbara F; Hébert, Terence E; Jean-Claude, Bertrand J; Laporte, Stéphane A; Moitessier, Nicolas R; Robaire, Bernard; Ward, Brian J
Keywords: Academia; Clinical Trials; Drug Discovery; Experimental Therapeutics; Industry
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Medicine
- Pediatrics
- Neurology and Neurosurgery
- Institut de génie biomédical
- Engineering Physics
- Biomedical Engineering
- Biology
- Other
Co-authors at McGill University, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Serge Gauthier
Faculty
2 shared papers, latest 2024
Jean-Paul Soucy
Institut de génie biomédical
2 shared papers, latest 2024
Kevin Petrecca
Neurology and Neurosurgery
2 shared papers, latest 2019
Janusz Rak
Pediatrics
2 shared papers, latest 2019
Kevin Petrecca
Engineering Physics
2 shared papers, latest 2019
Pedro Rosa-Neto
Neurology and Neurosurgery
2 shared papers, latest 2024
Serge Gauthier
Neurology and Neurosurgery
2 shared papers, latest 2024
Indra Gupta
Biology
1 shared papers, latest 2019
Jan Seuntjens
Medical Physics
1 shared papers, latest 2017
Jean-Jacques Lebrun
Medicine
1 shared papers, latest 2018
Suhad Ali
Medicine
1 shared papers, latest 2018
Kolja Eppert
Pediatrics
1 shared papers, latest 2019
Indra Gupta
Pediatrics
1 shared papers, latest 2019
Lawrence Panasci
Oncology
1 shared papers, latest 2007
Catalin Mihalcioiu
Medicine
1 shared papers, latest 2015
ATILLA Omeroglu
Biomedical Engineering
1 shared papers, latest 2015
Richard Kremer
Medicine
1 shared papers, latest 2018
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.